ZION Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zions Bancorporation (ZION) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown some positive financial performance and technical indicators, insider selling, neutral hedge fund sentiment, and lack of strong positive catalysts make it prudent to hold off on making a purchase right now. The pre-market price increase and upcoming earnings report may introduce volatility, but the lack of clear bullish signals suggests waiting for a better entry point.
The technical indicators show a bullish trend with SMA_5 > SMA_20 > SMA_200 and a MACD histogram above 0. However, the RSI at 71.186 is in the neutral zone, and the stock is trading near its resistance level (R1: 62.141). The stock has a 40% chance to increase by 0.28% in the next day but is likely to decline by -7.89% in the next week and -12.7% in the next month, indicating potential short-term downside risk.
The company's financial performance in Q4 2025 showed strong growth with a 30.81% YoY increase in net income and a 31.34% YoY increase in EPS. The pre-market price is up 1.10%, indicating some positive sentiment.
Insider selling has increased significantly by 2580.60% over the last month, and hedge funds remain neutral. Analyst ratings are mostly neutral, with multiple firms lowering their price targets recently. The stock has no recent news or significant positive catalysts, and the upcoming earnings report on April 20 could introduce uncertainty.
In Q4 2025, Zions Bancorporation reported revenue growth of 0.88% YoY to $801 million, net income growth of 30.81% YoY to $259 million, and EPS growth of 31.34% YoY to 1.76. These figures indicate strong financial performance, particularly in profitability metrics.
Analyst sentiment is mixed to neutral. Recent price target changes include reductions by BofA, Evercore ISI, Piper Sandler, and JPMorgan, with targets ranging from $62 to $68. Truist slightly raised its price target to $64 but maintained a Hold rating. Morgan Stanley and Baird upgraded the stock earlier in the year, citing attractive risk/reward and positive operating leverage.
